Antti Vuolanto
Chief Executive Officer at HERANTIS PHARMA OYJ
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Frans Gustaf Wuite | M | 64 |
Targovax Oy
 Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | 12 years |
| Henri Juhani Huttunen | M | - | 16 years | |
| Robert Forbes Burns | M | 77 |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | 9 years |
| Timo Ilari Veromaa | M | 64 | 12 years | |
| Diane Mellett | F | 64 | 9 years | |
| Mats Johan Peter Thorén | M | 53 | 4 years | |
| Hilde Furberg | F | 65 | 3 years | |
| J. Kenneth Charles Knowles | M | 77 |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | 13 years |
| Aki Pellervo Prihti | M | 53 | 10 years | |
| Tone Kvåle | F | 55 | 4 years | |
| Sari Pesonen | M | - |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | 11 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Pekka Ilmari Simula | M | 50 |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | 11 years |
| Craig Cook | M | 57 | - | |
| Ingrid Atteryd Heiman | F | 66 | - | |
| Per Anders Göte Samuelsson | M | 63 | 7 years | |
| Johan Rutger Christenson | M | 65 | 7 years | |
| Lars Lund-Roland | M | 68 | 2 years | |
| Eva-Lotta Allan | F | 65 | - | |
| Tuomas Mikael Riski | M | 45 |
Aalto University School of Science & Technology
| 2 years |
| Timo Olavi Vikström | M | 56 |
Aalto University School of Science & Technology
| 2 years |
| Ewa Laczkowska | M | - |
Aalto University School of Science & Technology
| 2 years |
| Jong-Hwa Jang | M | 65 |
Aalto University School of Science & Technology
| 1 years |
| Anna Valtonen | M | 50 |
Aalto University School of Science & Technology
| 3 years |
| Timo Olavi Ritakallio | M | 62 |
Aalto University School of Science & Technology
| 2 years |
| Kenneth Paqvalén | M | - |
Aalto University School of Science & Technology
| 1 years |
| Mikko Kärkkäinen | M | - |
Aalto University School of Science & Technology
| 3 years |
| Sami Joonas Järvinen | M | - |
Aalto University School of Science & Technology
| 4 years |
| Mika Ståhlberg | M | 51 |
Aalto University School of Science & Technology
| 1 years |
| Mika Saukkonen | M | - |
Aalto University School of Science & Technology
| 5 years |
| Christina Roitto | F | - |
Aalto University School of Science & Technology
| - |
| Gunnar Gårdemyr | M | 65 | 1 years | |
| Magnus Sjögren | M | 60 | - | |
| Johanna Småros | M | - |
Aalto University School of Science & Technology
| 3 years |
| Mikko Olavi Lampi | M | 47 |
Aalto University School of Science & Technology
| 1 years |
| Timo Mika Juhani Ahopelto | M | 49 |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | 5 years |
| Markus Aho | M | 44 |
Aalto University School of Science & Technology
| 1 years |
| Timo Petteri Linnainmaa | M | 48 |
Aalto University School of Science & Technology
| 3 years |
| Curt Mikael von Euler-Chelpin | M | 71 |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | - |
| Kimmo Alkio | M | 61 |
Aalto University School of Science & Technology
| 2 years |
| Kim Alarik Bergström | M | 66 |
Aalto University School of Science & Technology
| 1 years |
| Giedrius Vegys | M | 65 |
Aalto University School of Science & Technology
| 2 years |
| Joo-Ok Chang | M | 69 |
Aalto University School of Science & Technology
| 2 years |
| Charlotte Videbaek | M | 62 | - | |
| Mikko Kärkkäinen | M | - |
Aalto University School of Science & Technology
| 1 years |
| Antti Palmujoki | M | - |
Aalto University School of Science & Technology
| 3 years |
| Petteri Olli Hirvonen | M | 61 |
Aalto University School of Science & Technology
| 2 years |
| David J. Clifford | M | - |
Aalto University School of Science & Technology
| 2 years |
| Yuan Tian | F | 46 |
Aalto University School of Science & Technology
| 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Finland | 42 | 87.50% |
| Norway | 7 | 14.58% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Antti Vuolanto
- Personal Network
